Alnylam Pharmaceuticals (0HD2.L) Q3 2024 Earnings Report

In Q3 2024, Alnylam Pharmaceuticals (0HD2.L) reported a revenue decline of 33.26% year-over-year (YoY) to $500.9 million, which is a result of reduced demand for their RNAi therapeutics amid increasing competition in the biopharmaceutical sector. The net income showed a significant loss of $111.57 million, reflecting an increase in expenses and a pressurized profit margin. This quarter is particularly concerning as operating income and EBITDA also saw dramatic declines, indicating operational challenges that may require strategic adjustments. Management attributed the revenue fall to continued investment in R&D, which, while essential for long-term growth, is presently hampering profitability.